NxStage Medical, Inc. (NASDAQ:NXTM) has received a consensus recommendation of “Hold” from the ten brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and nine have given a hold rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $30.00.
A number of brokerages recently weighed in on NXTM. Zacks Investment Research raised NxStage Medical from a “sell” rating to a “hold” rating in a report on Friday. Canaccord Genuity reiterated a “hold” rating and set a $30.00 target price on shares of NxStage Medical in a research report on Tuesday, October 17th. Finally, Northland Securities reiterated a “hold” rating and set a $30.00 target price on shares of NxStage Medical in a research report on Wednesday, November 8th.
In other NxStage Medical news, SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $24.88, for a total transaction of $87,080.00. Following the sale, the senior vice president now directly owns 13,770 shares in the company, valued at $342,597.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 10,500 shares of company stock worth $265,860. 4.70% of the stock is owned by company insiders.
Shares of NxStage Medical (NASDAQ:NXTM) traded up $0.31 during mid-day trading on Friday, reaching $25.07. The company had a trading volume of 1,087,208 shares, compared to its average volume of 339,014. NxStage Medical has a 52-week low of $20.45 and a 52-week high of $30.80. The firm has a market capitalization of $1,639.91, a price-to-earnings ratio of -358.14 and a beta of -0.08.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.